FDA To Consider Annual COVID-19 Vaccine Strategy Similar To Flu Shots, Despite Lacking Evidence
To make amends of the White House’s ridiculous and out-of-touch “fully vaccinated” model, the Food and Drug Administration (FDA) is gearing up to change its COVID-19 vaccine strategy – again.
As most remember, originally Americans were told to take two doses of the original COVID-19 vaccine. Then – after that plan didn’t work out so well regarding efficacy – Americans were told they needed two additional boosters.
Some have already started making way on their fifth, sixth, and seventh boosters – and so on so forth.
To better hone in on its messaging, the FDA wants to adopt an approach similar to the flu vaccine through annually-updated shots.
The goal is to simplify vaccination against COVID and perhaps adopt an approach similar to what is used for the flu vaccine, with annual updates to match whatever strain of the virus is circulating. This is according to a federal official who spoke under the condition of anonymity because they were not authorized to speak publicly.
NPR reported the proposed shift early Monday morning, and later Monday the FDA outlined it publicly in a set of documents released in advance of a meeting Thursday of the agency’s Vaccine and Related Biological Products Advisory Committee (VRBPAC). The committee will vote on the agency’s proposal.
So just like with the annual flu vaccines, Americans may soon be expected to take a new shot in the fall that is said to be better equipped with tackling whatever new COVID-19 strain is prevalent in the country.
As expected, many medical professionals are already voicing their concerns with this new found “science.” Let alone the new FDA model for vaccinating Americans that the White House will surely begin parroting soon.
“We have no solid data about the performance of the bivalent boosters,” said John Moore, an immunologist at Weill Cornell Medical College.
“The hard evidence is lacking, and the evidence that is out there is at the very least inconclusive and to me trends towards saying the bivalent boosters were little if no better,” he added.
“We shouldn’t really be chasing these variants, which are evanescent and are often gone by the time you’ve created the vaccine,” says Dr. Paul Offit of the University of Pennsylvania.
The Vaccines and Related Biological Products Advisory Committee will meet on Thursday to discuss and vote on these potential COVID-19 vaccine changes.
Support Big League Politics by making a donation today. You can also donate via PayPal, Venmo or donate crypto. Your support helps us take on the powerful and report the truth that the mainstream media wants to silence.